Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B

Table 4 Comparison of tumor characteristics between patients with hepatocellular carcinoma with resistant chronic hepatitis B (R’ group) and hepatocellular carcinoma with chronic hepatitis B treated with antiviral treatment (N’ group): subgroup analysis based on tumor surveillance interval (≤ 6 mo) n (%)

Variables	R’ group (n = 37)	N’ group (n = 39)	P-value
Gender (male)	27 (73)	31 (79.5)	0.594
Age (mean, yr)	55.24 ± 7.94	56.08 ± 10.3	0.695
Presence of cirrhosis	36 (97.3)	39 (100)	1
Portal vein thrombosis	5 (13.5)	8 (20.5)	0.546
Vascular invasion	11 (29.7)	8 (20.5)	0.431
Multi-nodular tumor type	27 (73)	27 (69.2)	0.803
CLIP score	0.59 ± 0.72	0.97 ± 0.98	0.061
Modified UICC stage (< IVA)	34 (91.9)	35 (89.7)	1.0
Modified UICC stage (I/II/III/IVA/IVB)	11/11/12/3/0	11/15/9/2/2
LN involvement	0 (0)	2 (5.1)	0.496
Distant metastasis	0 (0)	1 (2.6)	1
AST U/L (median, range)	48 (20-141)	52 (16-481)	0.283
ALT U/L (median, range)	38 (8-199)	44 (11-150)	0.14
Platelet count (103/mm3) (median, range)	101 (23-232)	131 (24-260)	0.059
CRP (mg/dL) (median, range)	0.3 (0-2)	0.5 (0-16)	0.029
AFP IU/mL (median, range)	27 (2-737)	52 (3-16644)	0.039
Child-Pugh score	5.51 ± 0.85	5.91 ± 1.32	0.982
Duration of anti-viral Tx	21.5 (8-72)	7 (1-60)	< 0.001
Total follow-up duration	791.95 ± 643.06	1114.23 ± 646.84	0.033

UICC: Union Internationale Contre le Cancer; CLIP: Cancer of the Liver Italian Program; LN: Lymph node; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; HBV: Hepatitis B virus; CRP: C-reactive protein.